secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2024-09-30T23:59:59+00:00
Accession:  0001558370-24-013080
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroBo reports positive Phase 1 SAD data for DA-1726 obesity drug; no serious AEs
--------------------------------------------------------------------------------

- 45 obese participants randomized 6:3 DA-1726 vs placebo; drug safe and well tolerated.
- 5 AEs in DA-1726 group vs 3 placebo; no serious adverse events reported.
- Dose-linear PK observed across investigated range; additional cohorts added to find max tolerated dose.
- MAD Part 2 top-line data expected Q1 2025; Part 3 will evaluate early proof of concept.
- CEO cites potential best-in-class profile due to balanced GLP1R and glucagon receptor activation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024013080/0001558370-24-013080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024013080/nrbo-20240930x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-013080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer